MATHEW CASTELINO: Open Payments
NPI 1912970229 · GARY, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$376 in 20 payments from 11 companies in 2025. Trend: 2023 $977 · 2024 $865 · 2025 $376
Food & beverage: $376
| Company | Payments | Amount |
|---|---|---|
| Lundbeck LLC | 3 | $59 |
| E.R. Squibb & Sons, L.L.C. | 3 | $55 |
| Neurocrine BioSciences, Inc. | 3 | $45 |
| Otsuka America Pharmaceutical, Inc. | 2 | $40 |
| Teva Pharmaceuticals USA, Inc. | 2 | $33 |
| Vanda Pharmaceuticals Inc. | 2 | $33 |
| Indivior Inc. | 1 | $28 |
| Axsome Therapeutics, Inc. | 1 | $26 |
| Alkermes, Inc. | 1 | $21 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $19 |
Products named: REXULTI, COBENFY, INGREZZA, UZEDY, FANAPT, SUBLOCADE, Auvelity, ARISTADA.
Industry payments across IN — which companies pay providers there.
